Hepatocellular carcinoma.

被引:12
|
作者
Venook A.P. [1 ]
机构
[1] Division of Hematology and Oncology, University of California, 400 Parnassus Avenue, Suite 502, San Francisco, 94143, CA
关键词
Hepatocellular Carcinoma; Hepatic Artery; Octreotide; Chronic Liver Disease; Hepatic Resection;
D O I
10.1007/s11864-000-0068-z
中图分类号
学科分类号
摘要
Early detection of hepatocellular carcinoma (HCC) is feasible, particularly in patients known to be at risk from chronic hepatitis and chronic liver disease. The optimal surveillance strategy is unknown. HCC usually presents as an incurable disease even when detected on surveillance. Surgical resection is the treatment of choice, but the coexistence of chronic liver disease and the insidious nature of HCC make it unresectable in most patients. Orthotopic liver transplantation for selected patients or ablative techniques may offer an opportunity to render patients disease-free even if the tumor is unresectable. There are numerous therapies offered to patients with unresectable HCC, including chemotherapy, hormonal therapy, and regional intra-arterial treatments. While potentially palliative, none of these approaches has been demonstrated to prolong survival in these patients. If possible, the treatment of patients with HCC should be done on clinical trials.
引用
收藏
页码:407 / 414
页数:7
相关论文
共 50 条
  • [1] Hepatocellular carcinoma.
    Lemoine, A
    Azoulay, D
    Jezequel-Cuer, M
    Debuire, B
    PATHOLOGIE BIOLOGIE, 1999, 47 (09): : 903 - 910
  • [2] The management of hepatocellular carcinoma.
    Cerezo, FJM
    Garreta, J
    Miralbes, M
    Balanzo, J
    Enriquez, J
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1996, 88 (10) : 687 - 694
  • [3] Hepatic resection of hepatocellular carcinoma.
    Que, FG
    Gigot, JF
    Harmsen, WS
    Nagornev, DM
    HEPATOLOGY, 1997, 26 (04) : 466 - 466
  • [4] Cytotoxic chemotherapy for hepatocellular carcinoma.
    Beuzeboc, P
    SEMAINE DES HOPITAUX, 1996, 72 (21-22): : 654 - 659
  • [5] Hepatocellular carcinoma. Pathogenesis and multicentricity
    Blum, HE
    Hopt, UT
    CHIRURG, 2003, 74 (08): : 709 - 716
  • [6] Genetic alterations in hepatocellular carcinoma.
    Boige, V
    LaurentPuig, P
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (01): : 34 - 44
  • [7] The application of RNAi in hepatocellular carcinoma.
    黄锦
    林菊生
    中华肝脏病杂志, 2004, (09) : 49 - 49
  • [8] Colchicine delays hepatocellular carcinoma.
    Domville, D
    Arrieta, O
    Rodríguez, JL
    Rosas, V
    de León, SP
    Kershenobich, D
    Gómez-Roel, X
    León-Rodríguez, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 350S - 350S
  • [9] Hepatitis viruses and hepatocellular carcinoma.
    Rosmorduc, O
    Paterlini, P
    Poupon, R
    Brechot, C
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1999, 23 (03): : 363 - 375
  • [10] Telomerase,activity in hepatocellular carcinoma.
    Park, SH
    Kwon, SW
    Kim, KS
    Chae, KJ
    Oh, BK
    Park, YN
    Choi, JS
    Lee, WJ
    Park, C
    Kim, BR
    HEPATOLOGY, 2002, 36 (04) : 447A - 447A